HF Advisory Group LLC Has $1.52 Million Stock Position in Becton, Dickinson and Company $BDX

HF Advisory Group LLC increased its position in Becton, Dickinson and Company (NYSE:BDX) by 70.5% during the first quarter, Holdings Channel.com reports. The firm owned 9,666 shares of the medical instruments supplier’s stock after buying an additional 3,996 shares during the quarter. HF Advisory Group LLC’s holdings in Becton, Dickinson and Company were worth $1,520,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Poehling Capital Management INC. lifted its holdings in shares of Becton, Dickinson and Company by 12.5% in the first quarter. Poehling Capital Management INC. now owns 9,290 shares of the medical instruments supplier’s stock valued at $1,461,000 after purchasing an additional 1,035 shares in the last quarter. Grey Ledge Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 20.9% in the 1st quarter. Grey Ledge Advisors LLC now owns 2,800 shares of the medical instruments supplier’s stock worth $440,000 after buying an additional 484 shares during the last quarter. Aaron Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $249,000. Louisiana State Employees Retirement System bought a new position in Becton, Dickinson and Company during the first quarter valued at $2,280,000. Finally, Norway Savings Bank grew its stake in shares of Becton, Dickinson and Company by 6.2% during the 1st quarter. Norway Savings Bank now owns 7,125 shares of the medical instruments supplier’s stock worth $1,120,000 after acquiring an additional 413 shares during the period. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Zacks Research raised shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Argus decreased their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. Barclays increased their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Piper Sandler lowered their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Finally, Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $181.00.

Becton, Dickinson and Company Stock Up 3.1%

Shares of Becton, Dickinson and Company stock opened at $156.06 on Friday. The stock has a market capitalization of $43.00 billion, a price-to-earnings ratio of 39.51, a P/E/G ratio of 10.72 and a beta of 0.22. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The company’s 50 day moving average price is $148.17 and its 200-day moving average price is $170.75.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 5,188 shares of company stock valued at $765,120. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.